Bleeding and asymptomatic overdose in patients under Vitamin K antagonist therapy: Frequency and risk factors

• Main Authors: F. Ben Mbarka, K. Ben Jeddou, E. Allouche, I. Boukhris, N. Khalfallah, H. Baccar, Z. Ouahchi
• Format: Article
• Language: English
• Published: SpringerOpen 2018-03-01
• Series: The Egyptian Heart Journal
• Online Access: http://www.sciencedirect.com/science/article/pii/S1110260817302119

Background: Vitamin K antagonists are widely used in the treatment and prevention of thromboembolic disease. However, these drugs can cause serious side effects, especially bleeding. This study aims to evaluate frequency and risk factors of both bleeding and asymptomatic overdose in North African patients undergoing Vitamin K antagonist therapy. Methods: We performed a cross-sectional study in patients undergoing Vitamin K antagonist therapy. A statistical analysis has been conducted to identify overdose and bleeding risk factors by using chi-square test (p < .05). Results: One hundred and eleven patients were included. We recorded 14 cases of bleeding and 26 cases of asymptomatic overdose. Advanced age, poor adherence, concomitant use of paracetamol and history of previous bleeding are significant risk factors of over-anticoagulation. An INR value over 6 at admission, a high therapeutic target range for INR, concomitant use of acetylsalicylic acid, lack of information on overdose signs and measures to be taken in case of bleeding were identified as risk factors for bleeding. Conclusion: Most of the risk factors identified in our study seem to be related to patients lack of information and education. These results highlight the importance of creating a therapeutic patient education program. Keywords: Vitamin K antagonist, Bleeding, Risk factor, Overdose